[go: up one dir, main page]

WO2002000680A3 - Cationic steroid derivatives for gene delivery - Google Patents

Cationic steroid derivatives for gene delivery Download PDF

Info

Publication number
WO2002000680A3
WO2002000680A3 PCT/GB2001/002859 GB0102859W WO0200680A3 WO 2002000680 A3 WO2002000680 A3 WO 2002000680A3 GB 0102859 W GB0102859 W GB 0102859W WO 0200680 A3 WO0200680 A3 WO 0200680A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene delivery
steroid derivatives
cationic steroid
head group
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/002859
Other languages
French (fr)
Other versions
WO2002000680A2 (en
Inventor
Kam Man Hui
Hui Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NCC TECHNOLOGY Pte Ltd
STUART IAN
Original Assignee
NCC TECHNOLOGY Pte Ltd
STUART IAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NCC TECHNOLOGY Pte Ltd, STUART IAN filed Critical NCC TECHNOLOGY Pte Ltd
Priority to AU2001266189A priority Critical patent/AU2001266189A1/en
Publication of WO2002000680A2 publication Critical patent/WO2002000680A2/en
Publication of WO2002000680A3 publication Critical patent/WO2002000680A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel lipids for forming liposomes for use as nucleic acid delivery vehicles, e.g. for gene therapy, have structure with a steroid (cholesteryl) domain linked via a carbamoyl linkage to a head group which is positively charged in use (generally through protonation). The head group preferably comprises a nitrogen heterocycle, e.g. a piperazine or morpholine ring system.
PCT/GB2001/002859 2000-06-26 2001-06-26 Cationic steroid derivatives for gene delivery Ceased WO2002000680A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001266189A AU2001266189A1 (en) 2000-06-26 2001-06-26 Materials and methods relating to gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015624.0A GB0015624D0 (en) 2000-06-26 2000-06-26 Materials and methods relating to improved gene delivery
GB0015624.0 2000-06-26

Publications (2)

Publication Number Publication Date
WO2002000680A2 WO2002000680A2 (en) 2002-01-03
WO2002000680A3 true WO2002000680A3 (en) 2002-05-16

Family

ID=9894419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002859 Ceased WO2002000680A2 (en) 2000-06-26 2001-06-26 Cationic steroid derivatives for gene delivery

Country Status (3)

Country Link
AU (1) AU2001266189A1 (en)
GB (1) GB0015624D0 (en)
WO (1) WO2002000680A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109898A1 (en) 2001-02-21 2002-09-05 Novosom Gmbh Variable charge lipids
CN117003808A (en) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 A cationic lipid compound and its preparation method and use
CN115487168A (en) * 2022-09-27 2022-12-20 浙江大学 A kind of lipid nanoparticle based on nitrogen-containing heterocyclic cholesterol derivative and its application
CN120227354A (en) * 2023-12-29 2025-07-01 康希诺(上海)生物研发有限公司 Lipid nanoparticles for delivering nucleic acids and preparation method and use thereof
CN120271651A (en) * 2023-12-29 2025-07-08 康希诺(上海)生物研发有限公司 Ionizable cationic lipid compounds and compositions for nucleic acid delivery and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018372A2 (en) * 1994-12-09 1996-06-20 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1996040726A1 (en) * 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
WO1997004748A2 (en) * 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
WO1997039019A1 (en) * 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
WO1998045317A1 (en) * 1997-04-04 1998-10-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018372A2 (en) * 1994-12-09 1996-06-20 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1996040726A1 (en) * 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
WO1997004748A2 (en) * 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
WO1997039019A1 (en) * 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
WO1998045317A1 (en) * 1997-04-04 1998-10-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules

Also Published As

Publication number Publication date
GB0015624D0 (en) 2000-08-16
AU2001266189A1 (en) 2002-01-08
WO2002000680A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
Pichon et al. Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides
WO2002009767A3 (en) Therapeutic polyanhydride compounds for drug delivery
CA2381097A1 (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
WO1998005673A8 (en) Methods for purifying nucleic acids
WO2000065024A3 (en) Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
HK1042091A1 (en) Adamantane derivatives
EP1191098A3 (en) Pharmaceutical composition for treatment of duchenne muscular dystrophy
AU4180296A (en) Adjuvant for a vaccine composition
HK1005776A1 (en) Isoquinolines
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
WO2002005782A3 (en) Stable salts of o-acetylsalicyclic with basic amino acids
AU4398100A (en) Polyol mixture for the preparation of rigid polyurethane foams
WO2001047928A3 (en) Imidazo 1,3,5 triazinones and the use thereof
PL342514A1 (en) Liposomic erythropoietin suspension
DK0734252T3 (en) Vincaalkaloid vesicles with increased efficiency and tumor targeting properties
WO2002000680A3 (en) Cationic steroid derivatives for gene delivery
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
WO2004017943A3 (en) Non-vesicular cationic lipid formulations
WO2004105697A3 (en) Novel lipids for transfection of nucleic acids
HK1046902A1 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for their preparation
Islam et al. Efficient nucleic acid transduction with lipoplexes containing novel piperazine-and polyamine-conjugated cholesterol derivatives
EP1038896A3 (en) Amido functional amine catalysts for the production of polyurethanes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP